Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 2.94 (-2.00%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 2.94 (-2.00%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 2.94 (-2.00%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 2.94 (-2.00%)
Why Shares of AC Immune Jumped This Week

The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.

ACIU : 2.94 (-2.00%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 2.94 (-2.00%)
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 5.89 (-3.28%)
CNCE : 8.37 (+0.12%)
KYKOF : 16.6780 (-4.70%)
SFOSF : 1.8300 (+4.57%)
KHTRF : 4.0400 (-0.74%)
ACIU : 2.94 (-2.00%)
BMEA : 8.84 (-2.21%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 2.94 (-2.00%)
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...

ACIU : 2.94 (-2.00%)
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE...

ACIU : 2.94 (-2.00%)

Barchart Exclusives

Is This High-Yield Dividend Stock a Buy After Earnings?
This pharmaceutical giant's Q3 numbers came in ahead of Street estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar